Get the Stockscreener App
30.50
0.13%
-0.04
After Hours:
30.50
Xenon Pharmaceuticals Inc stock is traded at $30.50, with a volume of 754.16K.
It is down -0.13% in the last 24 hours and down -4.95% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$30.54
Open:
$30.29
24h Volume:
754.16K
Relative Volume:
0.62
Market Cap:
$2.34B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-11.13
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
+0.66%
1M Performance:
-4.95%
6M Performance:
-23.71%
1Y Performance:
-30.25%
1-Day Range:
$30.00
$30.74
1-Week Range:
$30.00
$31.87
52-Week Range:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
30.50 | 2.34B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
What drives Xenon Pharmaceuticals Inc. stock priceGet professional guidance for market timing - jammulinksnews.com
What are the latest earnings results for Xenon Pharmaceuticals Inc.Discover the fastest growing stocks today - jammulinksnews.com
When is Xenon Pharmaceuticals Inc. stock expected to show significant growthUnlock exclusive stock market insights - jammulinksnews.com
How does Xenon Pharmaceuticals Inc. compare to its industry peersFree Daily Trading Room Entry - jammulinksnews.com
What catalysts could drive Xenon Pharmaceuticals Inc. stock higher in 2025Capitalize on market trends before they peak - jammulinksnews.com
What is Xenon Pharmaceuticals Inc. company’s growth strategyRapid growth opportunities - jammulinksnews.com
Is Xenon Pharmaceuticals Inc. a good long term investmentBuild wealth with proven stock investing tactics - jammulinksnews.com
What’s the recovery path for long term holders of Xenon Pharmaceuticals Inc.Free Fundamental + Technical Hybrid Stock Tips - Newser
Xenon Pharmaceuticals Inc. Stock Analysis and ForecastCapitalize on market momentum for profits - jammulinksnews.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Federated Hermes Inc. - Defense World
Using data tools to time your Xenon Pharmaceuticals Inc. exitFree Oversold Recovery Opportunity Stocks - Newser
Is Xenon Pharmaceuticals Inc. still worth holding after the dipAI Trend Detection for Entry Timing - Newser
Is Xenon Pharmaceuticals Inc. stock poised for growthSmart Money Strategy for Growth Stocks - Newser
Is a relief rally coming for Xenon Pharmaceuticals Inc. holdersFree Accurate Technical Trend Reversal Picks - Newser
Is it the right time to buy Xenon Pharmaceuticals Inc. stockGain access to exclusive stock analysis - jammulinksnews.com
What is the dividend policy of Xenon Pharmaceuticals Inc. stockUnlock expert market analysis instantly - jammulinksnews.com
Is Xenon Pharmaceuticals Inc. stock overvalued or undervaluedFree Stock Market Knowledge Sharing - jammulinksnews.com
How volatile is Xenon Pharmaceuticals Inc. stock compared to the marketBreakneck growth rates - jammulinksnews.com
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - The Globe and Mail
Xenon Pharmaceuticals Inc. stock trend forecastSafe Investment Ideas with Growth Upside - Newser
Assetmark Inc. Has $669,000 Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Using economic indicators to assess Xenon Pharmaceuticals Inc. potentialHigh Reward Picks with Tight Risk Control - Newser
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Short Interest Update - Defense World
Visual analytics tools that track Xenon Pharmaceuticals Inc. performanceTechnical Screener for High Growth Stocks - Newser
Xenon Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Risk Managed Intraday Trade Alerts - Newser
Has Xenon Pharmaceuticals Inc. found a price floorRisk Managed Watchlist with Breakout Picks - Newser
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals Expands Team: Grants $739K in Stock Options to 6 New Hires - Stock Titan
Will Xenon Pharmaceuticals Inc. continue its uptrendDividend Strategy Summary With 10-Year Outlook - newser.com
Envestnet Asset Management Inc. Sells 4,447 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Can you recover from losses in Xenon Pharmaceuticals Inc.Free Entry Zone Strategy for Consistent Profit - Newser
Why Xenon Pharmaceuticals Inc. stock attracts strong analyst attentionTrend Confirmation Scanner with Entry Focus - Newser
How Xenon Pharmaceuticals Inc. stock performs during market volatilityFree Breakout Momentum Picks With Protection - Newser
Identifying reversal signals in Xenon Pharmaceuticals Inc.Chart Risk Profile for Capital Preservation - Newser
Sector ETF performance correlation with Xenon Pharmaceuticals Inc.Free Trade Insight With Community Collaboration - Newser
Skandinaviska Enskilda Banken AB publ Acquires 7,081 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Fiera Capital Corp - Defense World
Should I buy Xenon Pharmaceuticals Inc. stock before earningsFree Breakout Entry Signal Confirmation Tool - Newser
What technical models suggest about Xenon Pharmaceuticals Inc.’s comebackStock Portfolio Risk and Return Analysis - Newser
Xenon Pharmaceuticals Inc. Recovery Gathers Momentum on Chart SignalsTrend Analysis for Safer Trades Gains Popularity - metal.it
Published on: 2025-07-29 06:12:13 - metal.it
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):